Proposal of a novel diabetogenic mechanism involving the serpin PAI-1

BioEssays

Volumn 28, Issue 6, 2006, Pages 629-641

  Griffiths, Sarah L ^a   Grainger, David J ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; SERINE PROTEINASE;

AMINO ACID SEQUENCE; CLUSTER ANALYSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DOWN REGULATION; GENE CLUSTER; GENE CONTROL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MOLECULAR GENETICS; OBESITY; ONSET AGE; REVIEW; RISK FACTOR; UPREGULATION;

ANIMALS; DIABETES MELLITUS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINS; SUBSTRATE SPECIFICITY; SYNDROME; THROMBIN;

EID: 33745067189     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20418     Document Type: Review

References (74)

1. Reaven GM. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607.
2. Duncan BB, Schmidt MI. 2001. Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 119:122-127.
3. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. 2002. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137.
4. Nesto R. 2004. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 21:810-877.
5. Despres JP, Lemieux I, Prud'homme D. 2001. Treatment of obesity: need to focus on high risk abdominally obese patients. Bmj 322:716-720.
6. Montague CT, O'Rahilly S. 2000. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49:883-888.
7. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, et al. 2002. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 22:173-178.
8. Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K. 1996. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 16:381-385.
9. Sobel BE, Taatjes DJ, Schneider DJ. 2003. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 23:1979-1989.
10. Grainger DJ. 2004. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24:399-404.
11. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. 1995. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855.
12. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, et al. 1998. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 80:1029-1030.
13. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, et al. 2001. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 104:3063-3068.
14. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, et al. 2000. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 20:1150-1154.
15. Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, et al. 2003. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 23:78-84.
16. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, et al. 2004. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336-346.
17. Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ. 2001. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. Faseb J 15:1840-1842.
18. Riccio A, Pedone PV, Lund LR, Olesen T, Olsen HS, et al. 1992. Transforming growth factor beta 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene. Mol Cell Biol 12:1846-1855.
19. Evans RM, Barish GD, Wang YX. 2004. PPARs and the complex journey to obesity. Nat Med 10:355-361.
20. Eriksson P, Nilsson L, Karpe F, Hamsten A. 1998. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 18:20-26.
21. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, et al. 1993. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 13:338-346.
22. Nordt TK, Schneider DJ, Sobel BE. 1994. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 89:321-330.
23. Nordt TK, Sawa H, Fujii S, Sobel BE. 1995. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91:764.
24. Grant PJ, Kruithof EK, Felley CP, Felber JP, Bachmann F. 1990. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci (Lond) 79:513-516.
25. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, et al. 2004. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 279:22595-22604.
26. Czekay RP, Loskutoff DJ. 2004. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229:1090-1096.
27. Komissarov AA, Andreasen PA, Bodker JS, Declerck PJ, Anagli JY, et al. 2005. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem 280:1482-1489.
28. Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, et al. 1991. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 78:1254-1261.
29. Olson ST, Swanson R, Day D, Verhamme I, Kvassman J, et al. 2001. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin. Biochemistry 40:11742-11756.
30. van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H, et al. 1997. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 90:1874-1882.
31. Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D. 1993. Kinetics of inactivation of alphathrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 268:12367-12372.
32. Patston PA, Schapira M. 1994. Low-affinity heparin stimulates the nactivation of plasminogen activator inhibitor-1 by thrombin. Blood 84:1164-1172.
33. Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, et al. 1991. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 115:1773-1781.
34. Taylor NA, Van De Ven WJ, Creemers JW. 2003. Curbing activation: proprotein convertases in homeostasis and pathology. Faseb J 17:1215-1227.
35. Duckert P, Brunak S, Blom N. 2004. Prediction of proprotein convertase cleavage sites. Protein Eng Des Sel 17:107-112.
36. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. 1990. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 111:757-763.
37. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, et al. 1993. Transforming growth factor beta I null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774.
38. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699.
39. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. 1998. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 91:2005-2009.
40. Annes JP, Chen Y, Munger JS, Rifkin DB. 2004. Integrin alphaVbeta6-mediated activation of latent TGFbeta requires the latent TGF-beta binding protein-1. J Cell Biol 165:723-734.
41. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawier J, et al. 1998. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-1170.
42. Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainger DJ. 2001. A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions. J Vasc Res 38:256-265.
43. Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, et al. 2001. Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 158:305-316.
44. Furie B, Bing DH, Feldmann RJ, Robison DJ, Burnier JP, et al. 1982. Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J Biol Chem 257:3875-3882.
45. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF, et al. 1990. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 87:3530-3533.
46. Horrevoets AJ, Tans G, Smilde AE, van Zonneveld AJ, Pannekoek H. 1993. Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1. J Biol Chem 268:779-782.
47. Rezaie AR. 1998. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1. Biochemistry 37:13138-13142.
48. Constam DB, Robertson EJ. 1999. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J Cell Biol 144:139-149.
49. Jin HJ, Dunn MA, Borthakur D, Kim YS. 2004. Refolding and purification of unprocessed porcine myostatin expressed in Escherichia coli. Protein Expr Purif 35:1-10.
50. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, et al. 2004. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455-462.
51. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, et al. 2003. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111:1723-1732.
52. Siegfried G, Khatib AM, Benjannet S, Chretien M, Seidah NG. 2003. The proteolytic processing of proplatelet-derived growth factor-A at RRKR(86) by members of the proprotein convertase family is functionally correlated to platelet-derived growth factor-A-induced functions and tumorigenicity. Cancer Res 63:1458-1463.
53. Lehmann M, Andre F, Bellan C, Remacle-Bonnet M, Garrouste F, et al. 1998. Deficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells. Endocrinology 139:3763-3771.
54. Bergeron E, Basak A, Decroly E, Seidah NG. 2003. Processing of alpha4 integrin by the proprotein convertases: histidine at position P6 regulates cleavage. Biochem J 373:475-484.
55. Lissitzky JC, Luis J, Munzer JS, Benjannet S, Parat F, et al. 2000. Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. Biochem J 346:133-138.
56. Gao G, Westling J, Thompson VP, Howell TD, Gottschall PE, et al. 2002. Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. J Biol Chem 277:11034-11041.
57. Hu CC, Liang FX, Zhou G, Tu L, Tang CH, et al. 2005. Assembly of Urothelial Plaques: Tetraspanin Function in Membrane Protein Trafficking. Mol Biol Cell 16:3937-3950.
58. Chen J, Kuei C, Sutton S, Wilson S, Yu J, et al. 2005. Identification and pharmacological characterization of prokineticin 2beta as a selective ligand for prokineticin receptor 1. Mol Pharmacol 67:2070-2076.
59. Lonnqvist L, Reinhardt D, Sakai L, Peltonen L. 1998. Evidence for furin-type activity-mediated C-terminal processing of profibrillin-1 and interference in the processing by certain mutations. Hum Mol Genet 7:2039-2044.
60. Bitoun E, Micheloni A, Lamant L, Bonnart C, Tartaglia-Polcini A, et al. 2003. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet 12:2417-2430.
61. Srour N, Lebel A, McMahon S, Fournier I, Fugere M, et al. 2003. TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity. FEBS Lett 554:275-283.
62. Posthaus H, Dubois CM, Laprise MH, Grondin F, Suter MM, et al. 1998. Proprotein cleavage of E-cadherin by furin in baculovirus over-expression system: potential role of other convertases in mammalian cells. FEBS Lett 438:306-310.
63. Adams RH, Lohrum M, Klostermann A, Betz H, Puschel AW. 1997. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. Embo J 16:6077-6086.
64. Bratt T, Cedervall T, Akerstrom B. 1994. Processing and secretion of rat alpha 1-microglobulin-bikunin expressed in eukaryotic cell lines. FEBS Lett 354:57-61.
65. Seger D, Shaltiel S. 2000. Evidence showing that the two-chain form of vitronectin is produced in the liver by a selective furin cleavage. FEBS Lett 480:169-174.
66. Gauster M, Hrzenjak A, Schick K, Frank S. 2005. Endothelial lipase is inactivated upon cleavage by the members of the proprotein convertase family. J Lipid Res 46:977-987.
67. Hensbergen PJ, Verzijl D, Balog CI, Dijkman R, van der Schors RC, et al. 2004. Furin is a chemokinemodifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. J Biol Chem 279:13402-13411.
68. Nakayama K. 1997. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 327:625-635.
69. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A. 2003. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 162:439-447.
70. Roebroek AJ, Taylor NA, Louagie E, Pauli I, Smeijers L, et al. 2004. Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem 279:53442-53450.
71. Hedo JA, Kahn CR, Hayashi M, Yamada KM, Kasuga M. 1983. Biosynthesis and glycosylation of the insulin receptor. Evidence for a single polypeptide precursor of the two major subunits. J Biol Chem 258:10020-10026.
72. Pashmforoush M YY, Steiner DF. 1994. Exon 11 enhances insulin binding affinity and tyrosine kinase activity of the human insulin proreceptor. J Biol Chem 269:32639-32648.
73. Williams JF, McClam DA, Dull TJ, Ullrich A, Olefsky JM. 1990. Characterization of an insulin receptor mutant lacking the subunit processing site. J Biol Chem 265:8463-8469.
74. Yoshimasa Y, Seino S, Whittaker J, Kakehi T, Kosaki A, et al. 1988. Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science 240:784-787.